Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation

British Journal of Pharmacology

Volumn 171, Issue 5, 2014, Pages 1114-1128

  Pabreja, K ^a   Mohd, M A ^a   Koole, C ^a   Wootten, D ^a   Furness, S G B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

G protein coupled receptor; GLP 1; GLP 1R; glucagon like peptide 1 receptor; GPCR; type 2 diabetes

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIRAGLUTIDE; LIXISENATIDE; SITAGLIPTIN; VILDAGLIPTIN;

APPETITE; CARDIOVASCULAR FUNCTION; DRUG HALF LIFE; DRUG POTENTIATION; GLUCAGON RELEASE; HEART PROTECTION; HUMAN; INSULIN LIKE ACTIVITY; INSULIN SENSITIVITY; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STOMACH EMPTYING; UPREGULATION;

G PROTEIN-COUPLED RECEPTOR; GLP-1; GLP-1R; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GPCR; TYPE 2 DIABETES;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; PROTEIN CONFORMATION; RECEPTORS, GLUCAGON;

EID: 84895164679     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12313     Document Type: Review

References (210)

1. Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, et al. (2005). The inhibitory effects of peripheral administration of peptide YY 3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044: 127-131.
2. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A, (2004). Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89: 2078-2084.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
4. Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, et al. (2005). The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. J Neurochem 92: 798-806.
5. Arnolds S, Dellweg S, Clair J, Dain M-P, Nauck MA, Rave K, et al. (2010). Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 33: 1509-1515.
6. Balkan B, Li X, (2000). Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol 279: R1449-R1454.
7. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M, (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350.
8. Ban K, Kim KH, Cho CK, Sauve M, Diamandis EP, Backx PH, et al. (2010). Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151: 1520-1531.
9. Barragán JM, Eng J, Rodríguez R, Blázquez E, (1999). Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 277: E784-E791.
10. Barrera JG, D'Alessio DA, Drucker DJ, Woods SC, Seeley RJ, (2009). Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes 58: 2820-2827.
11. Baumgartner I, Pacheco-Lõpez G, Rüttimann EB, Arnold M, Asarian L, Langhans W, et al. (2010). Hepatic-portal vein infusions of glucagon-like peptide-1 reduce meal size and increase c-Fos expression in the nucleus tractus solitarii, area postrema and central nucleus of the amygdala in rats. J Neuroendocrinol 22: 557-563.
12. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH, (2011). Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 13: 982-989.
13. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, et al. (2008). Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874-R880.
14. Bird AP, Faltinek JR, Shojaei AH, (2001). Transbuccal peptide delivery: stability and in vitro permeation studies on endomorphin-1. J Control Release 73: 31-36.
15. Bock T, Pakkenberg B, Buschard K, (2003). The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. Apmis 111: 1117-1124.
16. Brandt I, Joossens J, Chen X, Maes M-B, Scharpé S, De Meester I, et al. (2005). Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}- pyrrolidine-2-carbonitrile). Biochem Pharmacol 70: 134-143.
17. Brown DX, Evans M, (2012). Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective. J Nutr Metab 2012: 1-10.
18. Bullock BP, Heller RS, Habener JF, (1996). Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978.
19. Bulotta A, Hui H, Anastasi E, Bertolotto C, Boros LG, Di Mario U, et al. (2002). Cultured pancreatic ductal cells undergo cell cycle re-distribution and beta-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol 29: 347-360.
20. Burmeister MA, Ferre T, Ayala JE, King EM, Holt RM, Ayala JE, (2012). Acute activation of central GLP-1 receptors enhances hepatic insulin action and insulin secretion in high-fat-fed, insulin resistant mice. Am J Physiol Endocrinol Metab 302: E334-E343.
21. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47.
22. Buteau J, Foisy S, Joly E, Prentki M, (2003). Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes 52: 124-132.
23. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Pénicaud L, et al. (2008). Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 57: 2577-2587.
24. Campos RV, Lee YC, Drucker DJ, (1994). Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134: 2156-2164.
25. Chepurny OG, (2002). Exendin-4 as a stimulator of rat insulin I gene promoter activity via bZIP/CRE interactions sensitive to serine/threonine protein kinase inhibitor Ro 31-8220. Endocrinology 143: 2303-2313.
26. Cornu M, Modi H, Kawamori D, Kulkarni RN, Joffraud M, Thorens B, (2010). Glucagon-like peptide-1 increases beta-cell glucose competence and proliferation by translational induction of insulin-like growth factor-1 receptor expression. J Biol Chem 285: 10538-10545.
27. Creutzfeldt W, (1979). The incretin concept today. Diabetologia 16: 75-85.
28. Dai H, Gustavson SM, Preston GM, Eskra JD, Calle R, Hirshberg B, (2008). Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab 10: 506-513.
29. Deacon CF, Johnsen AH, Holst JJ, (1995). Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
30. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. (2004). One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 53: 1187-1194.
31. Delgado-Aros S, Kim D-Y, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, et al. (2002). Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 282: G424-G431.
32. Drucker DJ, Asa S, (1988). Glucagon gene expression in vertebrate brain. J Biol Chem 263: 13475-13478.
33. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF, (1987). Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84: 3434-3438.
34. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, et al. (1997). Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 15: 673-677.
35. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. (2008). Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372: 1240-1250.
36. Dupre J, Ross SA, Watson D, Brown JC, (1973). Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37: 826-828.
37. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. (2003). Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9: 1173-1179.
38. Dzhura I, Chepurny OG, Leech CA, Roe MW, Dzhura E, Xu X, et al. (2011). Phospholipase C-ε links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans. Islets 3: 121-128.
39. Egan JM, Meneilly GS, Habener JF, Elahi D, (2002). Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 87: 3768-3773.
40. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. (1992). Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291.
41. Elahi D, Egan JM, Shannon RP, Meneilly GS, Khatri A, Habener JF, et al. (2008). GLP-1 (9-36) amide, cleavage product of GLP-1 (7-36) amide, is a glucoregulatory peptide. Obesity (Silver Spring) 16: 1501-1509.
42. Eliasson L, Ma X, Renström E, Barg S, Berggren P-O, Galvanovskis J, et al. (2003). SUR1 regulates PKA-independent cAMP-induced granule priming in mouse pancreatic B-cells. J Gen Physiol 121: 181-197.
43. Elrick H, Stimmler L, Hlad CJ, Arai Y, (1964). Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24: 1076-1082.
44. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. (2002). Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397.
45. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. (2003). Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-5158.
46. Fehmann HC, Habener JF, (1991). Homologous desensitization of the insulinotropic glucagon-like peptide-I (7-37) receptor on insulinoma (HIT-T15) cells. Endocrinology 128: 2880-2888.
47. Fehmann HC, Habener JF, (1992). Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology 130: 159-166.
48. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, et al. (2007). Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50: 2297-2300.
49. Flint A, Raben A, Astrup A, Holst JJ, (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520.
50. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB, (2005). β-cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54: 1808-1815.
51. Furness SG, Wootten D, Christopoulos A, Sexton PM, (2012). Consequences of splice variation on secretin family G protein-coupled receptor function. Br J Pharmacol 166: 98-109.
52. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, et al. (2005). Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076.
53. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC, (1990). Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′,5′-monophosphate formation. Endocrinology 126: 2164-2168.
54. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC, (2012). Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61: 1250-1262.
55. Göke R, Trautmann ME, Haus E, Richter G, Fehmann HC, Arnold R, et al. (1989). Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. Am J Physiol 257: G397-G401.
56. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP, (1995). Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7: 2294-2300.
57. González N, Acitores A, Sancho V, Valverde I, Villanueva- Peñacarrillo ML, (2005). Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 126: 203-211.
58. Gribble FM, Tucker SJ, Ashcroft FM, (1997). The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J 16: 1145-1152.
59. Gribble FM, Tucker SJ, Haug T, Ashcroft FM, (1998). MgATP activates the beta cell KATP channel by interaction with its SUR1 subunit. Proc Natl Acad Sci U S A 95: 7185-7190.
60. Griffioen KJ, Wan R, Okun E, Wang X, Lovett-Barr MR, Li Y, et al. (2011). GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 89: 72-78.
61. Gromada J, Holst JJ, Rorsman P, (1998). Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 435: 583-594.
62. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z, (2012). Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 29: 1260-1267.
63. Hansen L, Deacon CF, Orskov C, Holst JJ, (1999). Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: 5356-5363.
64. Harikumar KG, Morfis MM, Sexton PM, Miller LJ, (2008). Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor. J Mol Neurosci 36: 279-285.
65. Hatakeyama H, Kishimoto T, Nemoto T, Kasai H, Takahashi N, (2006). Rapid glucose sensing by protein kinase A for insulin exocytosis in mouse pancreatic islets. J Physiol (Lond) 570: 271-282.
66. Hatakeyama H, Takahashi N, Kishimoto T, Nemoto T, Kasai H, (2007). Two cAMP-dependent pathways differentially regulate exocytosis of large dense-core and small vesicles in mouse beta-cells. J Physiol (Lond) 582: 1087-1098.
67. Hayes MR, Skibicka KP, Grill HJ, (2008). Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 149: 4059-4068.
68. Heller RS, Aponte GW, (1995). Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-36) amide. Am J Physiol 269: G852-G860.
69. Heller RS, Kieffer TJ, Habener JF, (1997). Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 46: 785-791.
70. Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, et al. (2008). GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 20: 649-659.
71. Henry RR, Smith SR, Schwartz SL, Mudaliar SR, Deacon CF, Holst JJ, et al. (2011). Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes. Diabetes Obes Metab 13: 850-858.
72. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, et al. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78: 675-688.
73. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B, (1995). Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126.
74. Heymann E, Mentlein R, (1978). Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett 91: 360-364.
75. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA, (2009). Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol (Lond) 587: 4749-4759.
76. Holst JJ, (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
77. Holst JJ, Orskov C, Vagn Nielsen O, Schwartz TW, (1987). Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211: 169-174.
78. Hörsch D, Göke R, Eissele R, Michel B, Göke B, (1997). Reciprocal cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and GLP-1 receptor mRNA in pancreatic islets of rat. Pancreas 14: 290-294.
79. Hui H, Wright C, Perfetti R, (2001). Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50: 785-796.
80. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, et al. (1995). Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 58: 149-156.
81. Imeryüz N, Yeǧen BÇ, Bozkurt A, Coşkun T, Villanueva-Peñacarrillo ML, Ulusoy NB, (1997). Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273: G920-G927.
82. In't Veld P, Marichal M, (2010). Microscopic anatomy of the human islet of Langerhans. Adv Exp Med Biol 654: 1-19.
83. Jin SL, Han VK, Simmons JG, Towle AC, Lauder JM, Lund PK, (1988). Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271: 519-532.
84. Jorgensen R, Kubale V, Vrecl M, Schwartz TW, Elling CE, (2007). Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther 322: 148-154.
85. Kang G, Chepurny OG, Holz GG, (2001). cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic β-cells. J Physiol (Lond) 536: 375-385.
86. Kang G, Leech CA, Chepurny OG, Coetzee WA, Holz GG, (2008). Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic β-cells and rat INS-1 cells. J Physiol (Lond) 586: 1307-1319.
87. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR, (2011). Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103-3112.
88. Kanse SM, Kreymann B, Ghatei MA, Bloom SR, (1988). ScienceDirect.com-FEBS Letters-Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett 241: 209-212.
89. Kato T, Nagatsu T, Fukasawa K, Harada M, Nagatsu I, Sakakibara S, (1978). Successive cleavage of N-terminal Arg1-Pro2 and Lys3-Pro4 from substance P but no release of Arg1-Pro2 from bradykinin, by X-Pro dipeptidyl-aminopeptidase. Biochim Biophys Acta 525: 417-422.
90. Kemp DM, Habener JF, (2001). Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology 142: 1179-1187.
91. Kenny AJ, Booth AG, George SG, Ingram J, Kershaw D, Wood EJ, et al. (1976). Dipeptidyl peptidase IV, a kidney brush-border serine peptidase. Biochem J 157: 169-182.
92. Kieffer TJ, McIntosh CH, Pederson RA, (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596.
93. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, et al. (2005). (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H) -yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141-151.
94. Knudsen LB, Pridal L, (1996). Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435.
95. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL, et al. (2010). Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 78: 456-465.
96. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ, (2007). Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis 3: 597-601.
97. Körner M, Stöckli M, Waser B, Reubi JC, (2007). GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48: 736-743.
98. Kreymann B, Williams G, Ghatei MA, Bloom SR, (1987). Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304.
99. Lambeir AM, Durinx C, Proost P, Van Damme J, Scharpé S, De Meester I, (2001). Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett 507: 327-330.
100. Lankat-Buttgereit B, Göke R, Stöckmann F, Jiang J, Fehmann HC, Göke B, (1994). Detection of the human glucagon-like peptide 1(7-36) amide receptor on insulinoma-derived cell membranes. Digestion 55: 29-33.
101. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C, (1997). Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257-270.
102. Lausier J, Diaz WC, Roskens V, LaRock K, Herzer K, Fong CG, et al. (2010). Vagal control of pancreatic β-cell proliferation. Am J Physiol Endocrinol Metab 299: E786-E793.
103. Lawrence MC, Bhatt HS, Easom RA, (2002). NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes 51: 691-698.
104. Light PE, (2002). Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol Endocrinol 16: 2135-2144.
105. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, et al. (2008). Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 151: 123-129.
106. Llewellyn-Smith IJ, Verberne AJM, (2013). Central Regulation of Autonomic Functions. Oxford University Press: Oxford.
107. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, et al. (2012). Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes 61: 2753-2762.
108. Luque MA, González N, Márquez L, Acitores A, Redondo A, Morales M, et al. (2002). Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 173: 465-473.
109. McIntyre N, Holdsworth CD, Turner DS, (1964). New interpretation of oral glucose tolerance. Lancet 2: 20-21.
110. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. (2010). Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos 38: 1944-1953.
111. Matschinsky F, Liang Y, Kesavan P, Wang L, Froguel P, Velho G, et al. (1993). Glucokinase as pancreatic beta cell glucose sensor and diabetes gene. J Clin Invest 92: 2092.
112. Matschinsky FM, Glaser B, Magnuson MA, (1998). Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 47: 307-315.
113. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, et al. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53: 654-662.
114. Meier JJ, Kemmeries G, Holst JJ, Nauck MA, (2005). Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 54: 2212-2218.
115. Meier JJ, Gethmann A, Nauck MA, Götze O, Schmitz F, Deacon CF, et al. (2006). The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab 290: E1118-E1123.
116. Meneilly GS, McIntosh CHS, Pederson RA, Habener JF, Ehlers MRW, Egan JM, et al. (2003). Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 26: 837-842.
117. Mentlein R, Dahms P, Grandt D, Krüger R, (1993a). Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49: 133-144.
118. Mentlein R, Gallwitz B, Schmidt WE, (1993b). Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835.
119. Merchenthaler I, Lane M, Shughrue P, (1999). Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 403: 261-280.
120. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, et al. (1996). Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257-261.
121. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF, (1986). Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261: 11880-11889.
122. Mojsov S, Weir GC, Habener JF, (1987). Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619.
123. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J, (1997a). High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201-21206.
124. Montrose-Rafizadeh C, Yang H, Wang Y, Roth J, Montrose MH, Adams LG, (1997b). Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. J Cell Physiol 172: 275-283.
125. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, et al. (2010). Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53: 153-159.
126. Nagell CF, Wettergren A, Ørskov C, Holst JJ, (2006). Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs. Scand J Gastroenterol 41: 667-672.
127. Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A, (1996). Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol 271: E808-E813.
128. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al. (2004). Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 110: 36-43.
129. Näslund E, Gutniak M, Skogar S, Rössner S, Hellström PM, (1998). Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68: 525-530.
130. Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W, (1993a). Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917.
131. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W, (1993b). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307.
132. Nauck MA, Kemmeries G, Holst JJ, Meier JJ, (2011). Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60: 1561-1565.
133. Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP, (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408.
134. Nishizawa M, Nakabayashi H, Uchida K, Nakagaw A, Niijima A, (1996). The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-l, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. J Auton Nerv Syst 61: 149-154.
135. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, Morgan DA, Varela L, Haynes WG, et al. (2009). Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29: 5916-5925.
136. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, et al. (1997). Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 186: 1865-1872.
137. Orskov C, Poulsen SS, (1991). Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 40: 1292-1296.
138. Orskov C, Holst JJ, Poulsen SS, Kirkegaard P, (1987). Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30: 874-881.
139. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ, (1994). Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539.
140. Orskov C, Poulsen SS, Møller M, Holst JJ, (1996a). Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835.
141. Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, et al. (1996b). GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232.
142. Ozaki N, Shibasaki T, Kashima Y, Miki T, Takahashi K, Ueno H, et al. (2000). cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2: 805-811.
143. Panjwani N, Mulvihill EE, Longuet C, Yusta B, Campbell JE, Brown TJ, et al. (2013). GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE-/- mice. Endocrinology 154: 127-139.
144. Park JH, Kim SJ, Park SH, Son DG, Bae JH, Kim HK, et al. (2012). Glucagon-like peptide-1 enhances glucokinase activity in pancreatic β-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology 153: 574-582.
145. Patzelt C, Tager HS, Carroll RJ, Steiner DF, (1979). Identification and processing of proglucagon in pancreatic islets. Nature 282: 260-266.
146. Perfetti R, Zhou J, Doyle ME, Egan JM, (2000). Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141: 4600-4605.
147. Plamboeck A, Holst JJ, Carr RD, Deacon CF, (2005). Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 48: 1882-1890.
148. Pocai A, (2012). Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol 215: 335-346.
149. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. (2011). One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65: 397-407.
150. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. (2010). Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375: 1447-1456.
151. Preitner F, Ibberson M, Franklin I, Binnert C, Pende M, Gjinovci A, et al. (2004). Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 113: 635-645.
152. Prigeon RL, Quddusi S, Paty B, D'Alessio DA, (2003). Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. Am J Physiol Endocrinol Metab 285: E701-E707.
153. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, et al. (1998). Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett 432: 73-76.
154. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, et al. (1999). Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 274: 3988-3993.
155. Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J, (2000). Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 96: 1674-1680.
156. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, et al. (2010). GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285: 1989-2002.
157. Reid T, (2012). Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes 30: 3-12.
158. Renner E, Puskás N, Dobolyi A, Palkovits M, (2012). Glucagon-like peptide-1 of brainstem origin activates dorsomedial hypothalamic neurons in satiated rats. Peptides 35: 14-22.
159. Richter G, Göke R, Göke B, Arnold R, (1990). Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes. FEBS Lett 267: 78-80.
160. Richter G, Feddersen O, Wagner U, Barth P, Göke R, Göke B, (1993). GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 265: L374-L381.
161. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. (2002). The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283: E745-E752.
162. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, Albiglutide Study Group (2009). Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32: 1880-1886.
163. Rosenstock J, Balas B, Charbonnel B, Bolli GB, Boldrin M, Ratner R, et al. (2013). The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 36: 498-504.
164. Ruiz-Grande C, Alarcõn C, Alcántara A, Castilla C, Lõpez Novoa JM, Villanueva-Peñacarrillo ML, et al. (1993). Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25: 612-616.
165. Sancho V, Nuche B, Arnés L, Cancelas J, González N, Díaz-Miguel M, et al. (2007). The action of GLP-1 and exendins upon glucose transport in normal human adipocytes, and on kinase activity as compared to morbidly obese patients. Int J Mol Med 19: 961-966.
166. Sandoval DA, Bagnol D, Woods SC, D'Alessio DA, Seeley RJ, (2008). Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 57: 2046-2054.
167. Scheen AJ, (2012). DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab 38: 89-101.
168. Schepp W, Dehne K, Riedel T, Schmidtler J, Schaffer K, Classen M, (1996). Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 57: 398-405.
169. Schirra J, Wank U, Arnold R, Göke B, Katschinski M, (2002). Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut 50: 341-348.
170. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, et al. (2006). Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55: 243-251.
171. Schlatter P, Beglinger C, Drewe J, Gutmann H, (2007). Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 141: 120-128.
172. Schuit FC, Huypens P, Heimberg H, Pipeleers DG, (2001). Glucose sensing in pancreatic β-cells a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50: 1-11.
173. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258.
174. Seghieri M, Rebelos E, Gastaldelli A, Astiarraga BD, Casolaro A, Barsotti E, et al. (2013). Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia 56: 156-161.
175. Shibasaki T, Takahashi H, Miki T, Sunaga Y, Matsumura K, Yamanaka M, et al. (2007). Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A 104: 19333-19338.
176. Shughrue PJ, Lane MV, Merchenthaler I, (1996). Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137: 5159-5162.
177. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB, (2013). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 173: 534-539.
178. Skoglund G, Hussain MA, Holz GG, (2000). Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes 49: 1156-1164.
179. Song W-J, Seshadri M, Ashraf U, Mdluli T, Mondal P, Keil M, et al. (2011). Snapin mediates incretin action and augments glucose-dependent insulin secretion. Cell Metab 13: 308-319.
180. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu J-C, Olefsky JM, (2008). Beta-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic beta cells. Proc Natl Acad Sci U S A 105: 6614-6619.
181. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. (2000). Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49: 741-748.
182. Sturis J, Gotfredsen CF, Rømer J, Rolin B, Ribel U, Brand CL, et al. (2003). GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140: 123-132.
183. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, et al. (1996). Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271: R848-R856.
184. Tomas E, Habener JF, (2010). Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trends Endocrinol Metab 21: 59-67.
185. Tornehave D, Kristensen P, Rømer J, Knudsen LB, Heller RS, (2008). Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 56: 841-851.
186. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B, (2001). Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50: 1562-1570.
187. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. (1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
188. Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, et al. (2007). Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148: 4965-4973.
189. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA, (2000). Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 49: 611-617.
190. Vella A, Shah P, Reed A, Adkins A, Basu R, Rizza R, (2002). Lack of effect of exendin-4 and glucagon-like peptide-1-(7, 36)-amide on insulin action in non-diabetic humans. Diabetologia 45: 1410-1415.
191. Villanueva-Peñacarrillo ML, Delgado E, Trapote MA, Alcántara A, Clemente F, Luque MA, et al. (1995). Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146: 183-189.
192. Wan S, Browning KN, Travagli RA, (2007a). Glucagon-like peptide-1 modulates synaptic transmission to identified pancreas-projecting vagal motoneurons. Peptides 28: 2184-2191.
193. Wan S, Coleman FH, Travagli RA, (2007b). Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol Gastrointest Liver Physiol 292: G1474-G1482.
194. Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al. (2012). Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol 12: 2.
195. Wang Q, Brubaker PL, (2002). Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45: 1263-1273.
196. Wang X, Zhou J, Doyle ME, Egan JM, (2001). Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic β-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142: 1820-1827.
197. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C, (1995). Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136: 4910-4917.
198. Wang Y, Kole HK, Montrose-Rafizadeh C, Perfetti R, Bernier M, Egan JM, (1997). Regulation of glucose transporters and hexose uptake in 3T3-L1 adipocytes: glucagon-like peptide-1 and insulin interactions. J Mol Endocrinol 19: 241-248.
199. Washington MC, Raboin SJ, Thompson W, Larsen CJ, Sayegh AI, (2010). Exenatide reduces food intake and activates the enteric nervous system of the gastrointestinal tract and the dorsal vagal complex of the hindbrain in the rat by a GLP-1 receptor. Brain Res 1344: 124-133.
200. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ, (1994). Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29: 501-505.
201. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ, (1997). The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601.
202. Wettergren A, Wøjdemann M, Holst JJ, (1998). Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275: G984-G992.
203. Williams DL, Baskin DG, Schwartz MW, (2009). Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150: 1680-1687.
204. Xie T, Chen M, Zhang Q-H, Ma Z, Weinstein LS, (2007). Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc Natl Acad Sci U S A 104: 19601-19606.
205. Xu G, Stoffers DA, Habener JF, Bonner-Weir S, (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276.
206. Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S, (2006). GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract 73: 107-110.
207. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al. (2008). The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149: 574-579.
208. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. (2002). Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52.
209. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, et al. (2003). Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23: 2939-2946.
210. Zander M, Madsbad S, Madsen JL, Holst JJ, (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-830.